Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) COGS-to-Revenue : 0.53 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Anhui Wanbang Pharmaceutical Technology Co COGS-to-Revenue?

Anhui Wanbang Pharmaceutical Technology Co's Cost of Goods Sold for the three months ended in Mar. 2024 was ¥47.8 Mil. Its Revenue for the three months ended in Mar. 2024 was ¥90.2 Mil.

Anhui Wanbang Pharmaceutical Technology Co's COGS to Revenue for the three months ended in Mar. 2024 was 0.53.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Anhui Wanbang Pharmaceutical Technology Co's Gross Margin % for the three months ended in Mar. 2024 was 46.96%.

Anhui Wanbang Pharmaceutical Technology Co COGS-to-Revenue Historical Data

The historical data trend for Anhui Wanbang Pharmaceutical Technology Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anhui Wanbang Pharmaceutical Technology Co COGS-to-Revenue Chart

Anhui Wanbang Pharmaceutical Technology Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.52

0.44

0.47

0.50

0.51

Anhui Wanbang Pharmaceutical Technology Co Quarterly Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial									0.47	0.49	0.49	0.57	0.53

Anhui Wanbang Pharmaceutical Technology Co COGS-to-Revenue Calculation

Anhui Wanbang Pharmaceutical Technology Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	174.534	/	341.807
	=	0.51

Anhui Wanbang Pharmaceutical Technology Co's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	47.825	/	90.172
	=	0.53

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Anhui Wanbang Pharmaceutical Technology Co's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	47.825 / 90.172
	=	46.96 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Anhui Wanbang Pharmaceutical Technology Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Anhui Wanbang Pharmaceutical Technology Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anhui Wanbang Pharmaceutical Technology Co Ltd (SZSE:301520) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

N/A

Address

southwest corner of the intersection of Mingzhu Avenue and Huolongdi Road, Building 1, Anhui Wanbang Pharmaceutical, High-tech Zone, Anhui, Hefei, CHN, 230000

Website

http://www.ahwbyy.cn

Anhui Wanbang Pharmaceutical Technology Co Ltd is a one-stop CRO service platform that engages in the entire process from pharmaceutical development to clinical research of innovative drugs, improved new drugs and generic drugs. It aims to provide drug research and development and clinical trials for drug launch, including pharmaceutical research, clinical services, biological sample analysis and testing, SMO services and data statistics and analysis.

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Headlines

No Headlines